A nonrandomized phase II trial of sorafenib (S) and everolimus (E) in unresectable metastatic osteosarcoma (OST) patients (pts) relapsed after standard chemotherapy.
暂无分享，去创建一个
P. Casali | S. Ferrari | P. Picci | M. Aglietta | R. Biagini | V. Ferraresi | G. Grignani | F. Fagioli | R. Bertulli | M. Gambarotti | E. Palmerini | S. Asaftei | A. Tamburini | A. Nuzzo | Y. Pignochino | E. Marchesi | L. D'Ambrosio